Abstract
High-dose cyclophosphamide without stem cell rescue is a radical therapy for refractory autoimmune diseases.
The objective was to review the results of high-dose cyclophosphamide without stem cell rescue in autoimmune diseases. PubMed, Scielo, and Embase databases were systematically...
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Ingrid G. Rekeland; Kari Sørland; Lisbeth Lykke Neteland; Alexander Fosså; Kine Alme; Kristin Risa; Olav Dahl; Karl J. Tronstad; Olav Mella; Øystein...
https://bora.uib.no/bora-xmlui/handle/11250/3127770
Source: University of Bergen Date: May 2, 2024
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Clinical trials, medical treatment and pathomechanisms
------------------------------------------------------------
Ingrid Gurvin...
Full title:
Reduced endothelial function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - results from open-label cyclophosphamide intervention study
Provisionally accepted
https://www.frontiersin.org/articles/10.3389/fmed.2021.642710/abstract
published in frontiers in Medicine - Family Medicine and Primary Care
Results: The overall response rate by Fatigue score was 55.0% (22 of 40 patients). Fatigue score and other outcome variables showed significant improvements compared to baseline. The SF-36 Physical Function score increased...
Rituximab (RituxME)
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
Øystein Fluge and Olav Mella
BMC Neurology
2009
Link to article
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.